82353-55-7 Usage
Description
(S)-(1-METHYL-2-OXO-ETHYL)-CARBAMIC ACID BENZYL ESTER is a chemical compound that serves as an intermediate in the synthesis of various pharmaceuticals and bioactive molecules. It is characterized by its unique structure, which includes a carbamic acid group attached to a benzyl ester, and a chiral center that gives it the (S)-configuration. (S)-(1-METHYL-2-OXO-ETHYL)-CARBAMIC ACID BENZYL ESTER plays a crucial role in the development of enzyme inhibitors, amino sugars, and unusual amino acids, making it a valuable component in medicinal chemistry and drug discovery.
Uses
Used in Pharmaceutical Synthesis:
(S)-(1-METHYL-2-OXO-ETHYL)-CARBAMIC ACID BENZYL ESTER is used as an intermediate in the synthesis of N-protected α-amino aldehydes, which are essential components of peptide aldehydes with enzyme inhibitor activity. These inhibitors are vital for the development of drugs targeting specific enzymes involved in various diseases.
Used in Enzyme Inhibitor Development:
In the field of enzyme inhibitor development, (S)-(1-METHYL-2-OXO-ETHYL)-CARBAMIC ACID BENZYL ESTER is used as a key building block for the synthesis of Leupeptin, a well-known serine protease inhibitor. (S)-(1-METHYL-2-OXO-ETHYL)-CARBAMIC ACID BENZYL ESTER helps in the design and synthesis of new enzyme inhibitors with potential therapeutic applications.
Used in Amino Sugar Preparation:
(S)-(1-METHYL-2-OXO-ETHYL)-CARBAMIC ACID BENZYL ESTER is also used in the preparation of amino sugars, which are important components of various biologically active molecules, including antibiotics, antifungals, and antiviral agents. Amino sugars play a crucial role in the development of glycobiology and glycochemistry.
Used in Unusual Amino Acid Synthesis:
In the synthesis of unusual amino acids, (S)-(1-METHYL-2-OXO-ETHYL)-CARBAMIC ACID BENZYL ESTER serves as a valuable precursor. Unusual amino acids are essential for the development of novel peptides and proteins with unique properties and potential applications in various industries, including pharmaceuticals, agriculture, and materials science.
Check Digit Verification of cas no
The CAS Registry Mumber 82353-55-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,2,3,5 and 3 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 82353-55:
(7*8)+(6*2)+(5*3)+(4*5)+(3*3)+(2*5)+(1*5)=127
127 % 10 = 7
So 82353-55-7 is a valid CAS Registry Number.
82353-55-7Relevant articles and documents
Probing α-Amino Aldehydes as Weakly Acidic Pronucleophiles: Direct Access to Quaternary α-Amino Aldehydes by an Enantioselective Michael Addition Catalyzed by Br?nsted Bases
García-Urricelqui, Ane,de Cózar, Abel,Mielgo, Antonia,Palomo, Claudio
supporting information, p. 2483 - 2492 (2020/12/25)
The high tendency of α-amino aldehydes to undergo 1,2-additions and their relatively low stability under basic conditions have largely prevented their use as pronucleophiles in the realm of asymmetric catalysis, particularly for the production of quaternary α-amino aldehydes. Herein, it is demonstrated that the chemistry of α-amino aldehydes may be expanded beyond these limits by documenting the first direct α-alkylation of α-branched α-amino aldehydes with nitroolefins. The reaction produces densely functionalized products bearing up to two, quaternary and tertiary, vicinal stereocenters with high diastereo- and enantioselectivity. DFT modeling leads to the proposal that intramolecular hydrogen bonding between the NH group and the carbonyl oxygen atom in the starting α-amino aldehyde is key for reaction stereocontrol.
CHEMICAL COMPOUNDS
-
Page/Page column 132, (2020/06/01)
A compound of formula (I), wherein Ar1, R21, R23, R24, R25, R26, R27, A, X, Y and W are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
Aldolase-Catalyzed Asymmetric Synthesis of N-Heterocycles by Addition of Simple Aliphatic Nucleophiles to Aminoaldehydes
Roldán, Raquel,Hernández, Karel,Joglar, Jesús,Bujons, Jordi,Parella, Teodor,Fessner, Wolf-Dieter,Clapés, Pere
, p. 2673 - 2687 (2019/02/24)
Nitrogen heterocycles are structural motifs found in many bioactive natural products and of utmost importance in pharmaceutical drug development. In this work, a stereoselective synthesis of functionalized N-heterocycles was accomplished in two steps, com
